ProUroCare Medical Inc. · OTC:PUMD
ProUroCare Medical — Shareholder Meeting (August 2010)
15 slides from ProUroCare Medical's shareholder meeting presentation, Aug 10, 2010
Slide 1: ProUroCare Shareholders Meeting August 10, 2010
a ProUroCare a Proprietary Medical Imaging Technology Shareholders Meeting August 10, 2010
Slide 2: 2009-2010 Major Accomplishments
2009 — 2010 Major ae ProUroCare , — Accomplishments Raised $3.5 in new cash funding, $0.9 in conversions Completed FDA clinical study Submitted 510(k) to FDA Subsequently filed de novo submission Strengthened patent position of the company Transferred documentation from Artann to Logic Began product
Slide 3: ProUroCare Funding Since September 2009
ProUroCare Funding Since = September 2009 Net - $millions New cash funding » Warrant exchange offers $1.6 = Other warrant exercises 0.5 = Debt later converted to equity 0.9 = Other debt 05 Net new cash $3.5 Other » Existing debt converted to equity $0.9
Slide 4: ProUroCare Warrant Position
ProUroC: iti roUrotlare Warrant Position Millions $1.30 Exercise Price: Currently callable 3.6 Callable @ $4.00/share 28 Other warrants ($1.88 avg. exercise price) 1.0 Underwriter’s warrants ($1.20 cashless exercise) 0.6
Slide 5: FDA Status of ProUroScan System
FDA Status of ProUroC roUrolare ProUroScan System FDA clinical study completed in September 2009 510(k) submitted to FDA in November 2009 FDA response on 510(k) received in March 2010 NSE letter received from FDA in April 2010 Meeting at FDA on May 19, 2010 “De novo" submission filed with FDA on May
Slide 6: Summary of Current Patent Position
Summary of Current ProUroC ada Patent Position » Purchased 19 U.S. and foreign patents in 2008 » Acquired exclusive rights to new patent applications and all new patents and know how developed by Artann in our field of use (urology) = Completed freedom to operate assessment on existing patents » Rev
Slide 7: ProUroCare Manufacturing Scale Up at Logic
“Proure c Manufacturing a . Scale Up at Logic » Manufacturing documentation transfer from Artann to Logic essentially complete. » Parts ordered: = Off the shelf items: 95% complete « All obsolescence issues have been addressed « Special PCB orders will be placed in next 10 days « Fabricated parts be
Slide 8: ProUroCare Development of GMP/Documentation System
— ProUroCare Development of GMP/ ———~ Documentation System Allows ProUroCare to become the Registered Manufacturing Site. Required actions: « Hire manufacturing and quality people Develop documentation system Implement quality system at PUC Complete Manufacturing documentation Transfer 510(k) to Pro
Slide 9: ProUroCare Scientific Advisory Board
ProUroCare Scientific Advisory Board —— Contribute to ongoing refinement of the technology = Clinical applications = System configurations Participate in clinical studies including the development of research objectives, protocols and study end points Serve as Principal Investigators and authors of
Slide 10: ProUroCare SAB Status, 8.09.2010
ProUroCare SAB Status, 8.09.2010 ——— Dr. Robert Weiss Dr. Larry Goldenberg Robert Woods Johnson Medical Center University of British Columbia Dr. Richard Babayan David Crawf Boston University ty of Colorado Dr. Ajay Nehra Additional Engaged Clinical Resources: The M: di > alata Dr. Peter Scardino jo
Slide 11: ProUroCare Physician Comments From Meetings
“Proura c Physician Comments ro rovare From Meetings “| want to start using this on patients” - Key opinion leader urologist after demonstration “There is a lot of great math inside that box” - Head of biomedical engineering department “Even a general idea of [an abnormality’s] location is better th
Slide 12: ProUroCare Scientific Advisory Board: What's next for SAB?
ProUroCare Scientific Advisory Board —— What's next for SAB? 12 SAB meeting 9/18/2010 in Chicago SAB will define correlations studies and expanded clinical applications for our platform technology SAB will serve as training and reference sites SAB will validate future market and product strategies a
Slide 13: ProUroCare Business Model and Pricing
ProUroC ici roUrovare = Business Model and Pricing 2B Potential sources of revenue = Revenue from test and procedure components = Revenue from hardware systems and probes Patient pay model as interim approach Coverage with CPT code Medicare coverage position Creating new standard of care
Slide 14: ProUroCare Technology Development
“Proura c ProUroCare a . Technology Development System Configurations = Current cart based system (In review by FDA) - $19,000 = Lower cost cart based system (amendment) - $14,000 « Portable or brief case version of system — Target: <$10,000 Probes/Sensors = Cost reduction on sensor technology — Tar
Slide 15: Critical Steps to Commercialization of PMI
— Critical Steps to ProUroCare Commercialization of PMI 15 Produce minimum of 3 clinical units Complete production of new PPS probe Formalize approach for billing and data exchange Build training programs and materials Initiate Study Group clinical series Establish quality system at ProUroCare Trans
ProUroCare Medical — Shareholder Meeting (August 2010) on 6ix